Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1996 Sep;74(6):961-3.
doi: 10.1038/bjc.1996.465.

Paclitaxel for malignant pleural mesothelioma: a phase II study of the EORTC Lung Cancer Cooperative Group

J van Meerbeeck  1 , C Debruyne, N van Zandwijk, P E Postmus, M C Pennucci, F van Breukelen, D Galdermans, H Groen, P Pinson, M van Glabbeke, E van Marck, G Giaccone
Affiliations
Free PMC article
Clinical Trial

Paclitaxel for malignant pleural mesothelioma: a phase II study of the EORTC Lung Cancer Cooperative Group

J van Meerbeeck et al. Br J Cancer. 1996 Sep.
Free PMC article

Abstract

The EORTC Lung Cancer Cooperative Group undertook a phase II study of paclitaxel in 25 chemotherapy-naive patients with malignant pleural mesothelioma. Paclitaxel was given intravenously at a dose of 200 mg m-2 as a 3 h infusion every 3 weeks, after standard premedication with corticosteroids and antihistamines. This regimen was well tolerated, with < 4% of cycles resulting in severe toxicity. No major objective responses were observed and ten patients had stable disease. Median survival time was 39 weeks and the 1 year survival rate was 30%. In conclusion, paclitaxel at the dose and schedule investigated in this trial had no major activity in the treatment of malignant pleural mesothelioma.

PubMed Disclaimer

References

    1. Lung Cancer. 1994 Sep;11(3-4):305-8 - PubMed
    1. N Engl J Med. 1995 Apr 13;332(15):1004-14 - PubMed
    1. J Cell Physiol. 1983 Jan;114(1):137-44 - PubMed
    1. Mayo Clin Proc. 1988 Dec;63(12):1234-44 - PubMed
    1. Klin Wochenschr. 1988 Jul 15;66(14):607-13 - PubMed

Substances